Company signals
Elanco
2 signals in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: Against a Talent Market Index of 112.9 (Hot) (up 11.4 month-on-month), EMEA is at easing (-3.2pts) on signal share.
Elanco: 2 signals in the last 90 days; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 31 days.
Signals at Elanco
Capital Raising
AmericasElanco launches Elanco Ventures with $25 million multi-year commitment to invest in and accelerate innovation in animal health startups.
Leadership read: Fresh capital usually broadens the sector leadership bench strength — scale, go-to-market and operational depth — rather than any single appointment.
curated · 2026-06-18 · context →
Product Launch
EMEALaunched Befrena (tirnovetmab) anti-IL-31 monoclonal antibody for canine dermatology market
Leadership read: Product momentum tends to widen the sector product and commercial leadership bench strength.
curated · 2026-05-18 · context →
MitchelLake in this thematic
More signals across EMEA
Product Launch · EMEA
Siteimprove →Siteimprove launched a new MCP (Model Context Protocol) Server that integrates accessibility capabilities into AI workflows across Lovable, Anthropic Claude, VS Code, and Figma, enabling automated accessibility in digital experience creation.
Product Launch · EMEA
ST Engineering →ST Engineering secured a US$87.1 million UK defence contract to provide nine variants of 40mm high and low velocity grenades to the military.
Product Launch · EMEA
CSL →CSL's Tavenos product faced a regulatory setback in the European Union, flagged as a potential challenge to the biotechnology major
Product Launch · EMEA
JFrog →JFrog is gaining analyst momentum for AI-focused tools and software supply chain security offerings, with strong traction in managing AI development workflows and securing cloud-native software pipelines.
Product Launch · EMEA
Globant →Globant introduced AI Pods-powered Synthetic Operator for automated live-stream monitoring, targeting mission-critical media workflows with agentic AI tools.
Product Launch · EMEA
MSD →MSD's pembrolizumab received NICE recommendation for locally advanced cervical cancer (LACC), representing first immunotherapy approval in this indication in England
Intelligence powered by Autonodal ↗
